Press Releases

07.16.2020
Iveric Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
06.30.2020
Iveric Bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
06.22.2020
Iveric Bio Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
06.18.2020
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
06.17.2020
Iveric Bio Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement
06.15.2020
Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial
06.14.2020
Iveric Bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020
06.02.2020
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05.27.2020
Iveric Bio to Present at the Jefferies 2020 Healthcare Conference
05.06.2020
Iveric Bio Reports First Quarter 2020 Operational Highlights and Financial Results